Vestpro Financial Partners Inc. dba CPF Texas bought a new position in Allergan plc (NYSE:AGN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 2,253 shares of the company’s stock, valued at approximately $369,000.
Other hedge funds have also recently modified their holdings of the company. Cable Hill Partners LLC increased its holdings in shares of Allergan by 255.2% during the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after acquiring an additional 370 shares during the last quarter. Rockefeller Financial Services Inc. increased its holdings in shares of Allergan by 283.7% during the 3rd quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock valued at $111,000 after acquiring an additional 400 shares during the last quarter. BB&T Investment Services Inc. increased its holdings in shares of Allergan by 1,308.2% during the 3rd quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock valued at $139,000 after acquiring an additional 641 shares during the last quarter. Phocas Financial Corp. acquired a new position in shares of Allergan during the 2nd quarter valued at about $150,000. Finally, Acropolis Investment Management LLC acquired a new position in shares of Allergan during the 4th quarter valued at about $153,000. 79.76% of the stock is currently owned by institutional investors.
Shares of Allergan plc (NYSE:AGN) opened at $164.04 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.88 and a current ratio of 2.04. Allergan plc has a 52 week low of $156.00 and a 52 week high of $256.80. The firm has a market capitalization of $54,700.00, a P/E ratio of -13.68, a P/E/G ratio of 1.16 and a beta of 1.19.
Allergan (NYSE:AGN) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $4.86 EPS for the quarter, topping the Zacks’ consensus estimate of $4.74 by $0.12. Allergan had a positive return on equity of 8.28% and a negative net margin of 26.32%. The company had revenue of $4.33 billion during the quarter, compared to the consensus estimate of $4.28 billion. During the same quarter last year, the company earned $3.90 EPS. The company’s quarterly revenue was up 12.0% on a year-over-year basis. equities analysts forecast that Allergan plc will post 15.57 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be given a $0.72 dividend. The ex-dividend date is Tuesday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.76%. This is an increase from Allergan’s previous quarterly dividend of $0.70. Allergan’s dividend payout ratio (DPR) is currently -23.35%.
In other news, Director Chris W. Bodine acquired 3,030 shares of Allergan stock in a transaction on Thursday, December 7th. The stock was bought at an average price of $164.77 per share, for a total transaction of $499,253.10. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider William Meury sold 58,879 shares of the firm’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $160.62, for a total value of $9,457,144.98. The disclosure for this sale can be found here. Insiders acquired a total of 17,630 shares of company stock valued at $2,890,057 in the last quarter. Corporate insiders own 0.36% of the company’s stock.
AGN has been the topic of a number of analyst reports. Cowen set a $280.00 price objective on Allergan and gave the company a “buy” rating in a report on Friday, October 20th. JPMorgan Chase & Co. set a $275.00 price objective on Allergan and gave the company a “buy” rating in a report on Sunday, October 22nd. Zacks Investment Research raised Allergan from a “sell” rating to a “hold” rating in a report on Monday, October 23rd. Royal Bank of Canada set a $250.00 price objective on Allergan and gave the company a “buy” rating in a report on Sunday, October 29th. They noted that the move was a valuation call. Finally, Cantor Fitzgerald set a $231.00 price objective on Allergan and gave the company a “hold” rating in a report on Wednesday, November 1st. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $227.23.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.